Fairmount Funds Management LLC
CIK 1802528 · last filed 2026-09-03
Fairmount Funds Management LLC is a corporate insider who has filed 29 SEC Form 4 insider transactions across 8 companies since 2020. The most recent filing, for APGE, was dated Sep 3, 2026. Across all open-market trades the lifetime net is −$1.33B, making them a net seller over the disclosed history. Current disclosed insider exposure totals $298.6M across reported positions. The firm reports its address in West Conshohocken, PA. 51 SEC filings were submitted jointly with Fairmount Healthcare Fund II L.P.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$298.60M
8
29
-$1.33B
Filer Profile
SUITE 400
WEST CONSHOHOCKEN, PA 19428
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| APGE | Director | 0 | $135.07 | $0 | $0 | 2 | 2026-09-03 |
| SYRE | Director | 0 | $90.60 | $0 | -$1.60B | 3 | 2026-06-23 |
| JBIO | Director | — | $17.89 | — | $0 | 1 | 2026-06-11 |
| VRDN | Director | 5,090,928 | $21.24 | $108.13M | $279.99M | 6 | 2026-05-13 |
| COGT | Director | 5,503,418 | $33.41 | $183.87M | -$82.90M | 7 | 2026-01-22 |
| CRESCENT BIOPHARMA, INC. (GLYC) Delisted | Director | 2,747,866 | $15.70 | $43.14M | $72.95M | 1 | 2025-12-08 |
| DNTH | Director | 62,146 | $106.20 | $6.60M | $0 | 2 | 2024-04-01 |
| Cogent Biosciences, Inc. (UMRX) Delisted | 10%+ Owner | 1,147,406 | — | — | $0 | 2 | 2020-07-13 |
Recent Filings
29 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-09-03 | APGE | Disp (D) | −1,772,748 | $0 | EDGAR |
| 2026-07-01 | ORKA | Notice (144) | −3,553,410 | -$300.01M | EDGAR |
| 2026-06-23 | SYRE | Notice (144) | −4,684,781 | -$399.66M | EDGAR |
| 2026-06-23 | SYRE | Mixed | −16,072,404 | -$1.60B | EDGAR |
| 2026-06-11 | JBIO | Grant (A) | — | $0 | EDGAR |
| 2026-05-13 | VRDN | Buy (P) | +3,529,410 | $60.00M | EDGAR |
| 2026-03-31 | COGT | Notice (144) | −7,000,000 | -$242.62M | EDGAR |
| 2026-01-22 | COGT | Sell (S) | −3,500,000 | -$127.40M | EDGAR |
| 2026-01-22 | COGT | Notice (144) | −3,500,000 | -$127.40M | EDGAR |
| 2026-01-22 | APGE | Notice (144) | −1,750,000 | -$133.53M | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.